Email this article A prognostic model of the effect of the antiviral drug Relenza on the epidemic of A(H1N1)/2009 influenza
- Issue: Vol 56, No 5 (2011)
- Pages: 26-30
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.10.2011
- URL: https://virusjour.crie.ru/jour/article/view/12101
- ID: 12101
Cite item
Full Text
Abstract
The paper gives the results of calculation-theoretical studies estimating the effect of the etiotropic agent Relenza (in preventing influenza in its susceptible patients an in treating patients ill with influenza) on the epidemic of pandemic A(H1N1)/2009 influenza in a large city of Russia. The values of its effect (the number of prevented cases of influenza and that of prevented deaths from its complications) have been calculated on a computer, by applying a modified PSEEI2RF influenza epidemic model (a Russian Baroyan-Rvachev model) with the A(H1N1)/2009 influenza pathogen that dominated in the 2009-2010 season in many countries of the world.
Predictive estimates of the action of Relenza on the epidemic of A(H1N1)/2009 influenza have been obtained for 5 scenarios while implementing measures to treat patients with the illness and to prevent its susceptible patients in a large city with a population of one million.
In conclusion, there are results of predicting the number of prevented A(H1N1)/2009 influenza cases and damage estimates for 6 cities of Russia due to the massive use of the antiviral drug Relenza.
Predictive estimates of the action of Relenza on the epidemic of A(H1N1)/2009 influenza have been obtained for 5 scenarios while implementing measures to treat patients with the illness and to prevent its susceptible patients in a large city with a population of one million.
In conclusion, there are results of predicting the number of prevented A(H1N1)/2009 influenza cases and damage estimates for 6 cities of Russia due to the massive use of the antiviral drug Relenza.
References
- Бароян О. В., Рвачев Л. А., Иванников Ю. Г. Моделирование и прогнозирование эпидемий гриппа на территории СССР. - М., 1977.
- Боев Б. В. Модель развития эпидемии гриппа A(H1N1) в России в сезон 2009-2010 годов // Эпид. и вакцинопрофилактика. - 2010. - № 1. - С. 52-57.
- Ершов Ф. И. Антивирусные препараты: Справочник. - М., 2006.
- Карпухин Г. И. Профилактика и лечение гриппа. - Л., 1991.
- Киселев О. И., Ершов Ф. И., Быков А. Т., Покровский В. И. Пандемия гриппа 2009/2010: противовирусная терапия и тактика лечения. - СПб., 2010.
- Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. Writing committee of the WHO consultation on clinical aspects of pandemic (H1N1) 2009 influenza // N. Engl. J. Med. - 2010. - Vol. 362. - P. 1708-1719.
- LaForce C., Man C. Y., Henderson F. W. et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial // Clin. Ther. - 2007. - Vol. 29, N 8. - P. 1579- 1590.
- Mákelá M. J., Pauksens K., Rostila T. et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study // J. Infect. - 2000. - Vol. 40, N 1. - P. 42-48.
- Monto A. S., Pichichero M. E., Blanckenberg S. J. et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households // J. Infect. Dis. - 2002. - Vol. 186, N 11. - P. 1582.
- Peng A. W., Milleri S., Stein D. S. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation // Antimicrob. Agents Chemother. - 2000. - Vol. 44, N 7. - P. 1974.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).